The histone deacetylase inhibitors sodium butyrate and trichostatin A modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression

被引：0
|
作者：
VanOosten, RL [1 ]
Moore, JM [1 ]
Karacay, B [1 ]
Griffith, TS [1 ]
机构：
[1] Univ Iowa, Iowa City, IA 52242 USA
来源：
FASEB JOURNAL | 2005年 / 19卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A1405 / A1406
页数：2
相关论文
共 50 条
  • [1] Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/apo-2L-induced apoptosis by enhancing TRAIL-R2 expression
    VanOosten, RL
    Moore, JM
    Karacay, B
    Griffith, TS
    CANCER BIOLOGY & THERAPY, 2005, 4 (10) : 1104 - 1112
  • [2] Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
    Nakata, S
    Yoshida, T
    Horinaka, M
    Shiraishi, T
    Wakada, M
    Sakai, T
    ONCOGENE, 2004, 23 (37) : 6261 - 6271
  • [3] Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
    Susumu Nakata
    Tatsushi Yoshida
    Mano Horinaka
    Takumi Shiraishi
    Miki Wakada
    Toshiyuki Sakai
    Oncogene, 2004, 23 : 6261 - 6271
  • [4] The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis
    Griffith, TS
    Kemp, TJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) : 175 - 184
  • [5] The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis
    Thomas S. Griffith
    Troy J. Kemp
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 175 - 184
  • [6] TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells
    Szliszka, Ewelina
    Mazur, Bogdan
    Zydowicz, Grzegorz
    Czuba, Zenon P.
    Krol, Wojciech
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2009, 47 (04) : 579 - 585
  • [7] Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis
    Yoshida, Tatsushi
    Shiraishi, Takumi
    Horinaka, Mano
    Nakata, Susumu
    Yasuda, Takashi
    Goda, Ahmed E.
    Wakada, Miki
    Mizutani, Yoichi
    Miki, Tsuneharu
    Nishikawa, Akiyoshi
    Sakai, Toshiyuki
    CANCER SCIENCE, 2007, 98 (09) : 1417 - 1423
  • [8] Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
    Déjosez, M
    Ramp, U
    Mahotka, C
    Krieg, A
    Walczak, H
    Gabbert, HE
    Gerharz, CD
    CELL DEATH AND DIFFERENTIATION, 2000, 7 (11): : 1127 - 1136
  • [9] Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
    M Déjosez
    U Ramp
    C Mahotka
    A Krieg
    H Walczak
    H E Gabbert
    C D Gerharz
    Cell Death & Differentiation, 2000, 7 : 1127 - 1136
  • [10] A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells
    I Petak
    R Vernes
    K S Szucs
    M Anozie
    K Izeradjene
    L Douglas
    D M Tillman
    D C Phillips
    J A Houghton
    Cell Death & Differentiation, 2003, 10 : 729 - 739
12345